Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors

  • Eur J Med Chem. 2017 Feb 15:127:1025-1034. doi: 10.1016/j.ejmech.2016.11.012.
Ilhem Khelifi  1 Timothée Naret  1 Dolor Renko  1 Abdallah Hamze  1 Guillaume Bernadat  1 Jérome Bignon  2 Christine Lenoir  2 Joëlle Dubois  2 Jean-Daniel Brion  1 Olivier Provot  3 Mouad Alami  4
Affiliations
  • 1. BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France.
  • 2. Institut de Chimie des Substances Naturelles, UPR 2301, CNRS Avenue de La Terrasse, F-91198 Gif sur Yvette, France.
  • 3. BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France. Electronic address: [email protected].
  • 4. BioCIS, Univ. Paris-Sud, CNRS, Université Paris-Saclay, 92290, Châtenay-Malabry, France. Electronic address: [email protected].
Abstract

The synthesis and evaluation of a new series of IsoCombretaQuinolines (IsoCoQuines) 2 with a 2-substituted-quinoline in place of the 3,4,5-trimethoxyphenyl ring present in isoCA-4 and CA-4 are described. Most of these compounds displayed a potent cytotoxic activity (IC50 < 10 nM) against a panel of five human Cancer cell lines and inhibited tubulin assembly at a micromolar level. The most potent analogue 2b, having a 3-hydroxy-4-methoxyphenyl as B-ring, led to cell cycle arrest in G2/M phase. Docking studies indicate that 2b showed a binding mode comparable to those previously observed with quinazoline analogous (IsoCoQ) and with isoCA-4 at the colchicine binding site of tubulin.

Keywords
Binding; Cancer; Cytotoxicity; Quinoline; Tubulin; isoCA-4.